YOLFTbeta
Immunitybio Inc

Immunitybio Inc

IBRX · NASDAQ · Healthcare / Biotechnology

6.02USD-0.05 (-0.82%)

Price History

Full chart

Market Stats

Previous Close6.07
Open6.11
Day Range5.83 – 6.17
52-Week Range1.95 – 12.43
Volume13.30M
Market Cap9.46B
P/E (TTM)0.00
Forward P/E83.33
EPS-0.96
Dividend Yield0.00%
Beta0.17
50-Day Avg8.72
200-Day Avg7.94

About

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Richard Gerald Adcock
  • Employees684
  • Headquarters3530 John Hopkins Court, San Diego, CA, United States, 92121, USA
  • Websitehttps://immunitybio.com

Leadership

  • Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc.Founder, Executive Chairman and Global Chief Scientific & Medical Officer · b. 1953
  • Mr. Richard Gerald AdcockPresident, CEO & Director · b. 1969
  • Mr. David C. SachsChief Financial Officer · b. 1978
  • Ms. Regan J. LauerChief Accounting Officer · b. 1970
  • Dr. Barry J. Simon M.D.Chief Corporate Affairs Officer & Director · b. 1965
  • Dr. Enrique Diloné Ph.D., RACChief Technology Officer · b. 1967
  • Ms. Sarah SingletonChief Communications Officer & Head of Patient Advocacy
  • Ms. Emily ArisonSenior Vice President of Human Resources
  • Dr. Leonard S. Sender M.D.Chief Medical Officer of Liquid Tumors & Cell Therapy
  • Dr. Sandeep K. Reddy M.D.Chief Medical Officer

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue600.00K641.00K236.00K44.00K45.00K47.00K43.00K605.00K934.00K240.00K622.00K14.74M113.29M
Growth (%)-+6.83%-63.18%-81.36%+2.27%+4.44%-8.51%+1306.98%+54.38%-74.30%+159.17%+2270.58%+668.31%
Cost of Revenue253.00K323.00K----3.11M9.01M9.15M-24.19M18.51M17.55M753.00K
Gross Profit347.00K641.00K236.00K44.00K45.00K3.16M-8.97M605.00K934.00K240.00K622.00K14.74M112.53M
Gross Margin57.83%100.00%100.00%100.00%100.00%6717.02%-20858.14%100.00%100.00%100.00%100.00%100.00%99.34%
Operating Expense2.62M6.85M239.11M124.54M99.17M101.55M57.94M221.49M331.21M351.54M362.87M358.93M368.56M
Operating Income-2.27M-6.21M-238.88M-124.50M-99.12M-98.39M-66.91M-220.88M-330.28M-351.30M-362.25M-344.18M-256.03M
Operating Margin-378.17%-969.11%-101218.64%-282954.55%-220266.67%-209338.30%-155597.67%-36509.09%-35361.88%-146374.17%-58239.55%-2334.23%-226.00%
EBITDA-1.58M-5.68M-235.71M-117.71M-90.73M-86.74M-51.83M-204.22M-320.75M-351.88M-478.66M-264.43M-223.56M
EBITDA Margin-263.17%-885.65%-99875.00%-267518.18%-201626.67%-184555.32%-120523.26%-33755.37%-34341.76%-146617.08%-76955.47%-1793.37%-197.34%
Net Income-2.05M-6.21M-236.88M-120.81M-96.42M-96.23M-65.79M-221.85M-346.79M-416.57M-583.20M-413.56M-351.40M
Net Income Margin-341.17%-969.27%-100371.19%-274565.91%-214273.33%-204736.17%-152997.67%-36669.59%-37129.55%-173569.58%-93761.41%-2804.77%-310.18%
R&D446.00K1.59M11.43M26.55M39.78M53.42M48.88M139.51M195.96M248.15M232.37M190.14M207.88M
R&D as % of Total Revenue74.33%248.83%4844.92%60331.82%88395.56%113655.32%113686.05%23059.01%20980.51%103395.42%37357.88%1289.55%183.49%
Interest Expense463.00K0066.00K618.00K433.00K5.92M9.07M14.85M47.15M86.72M131.66M112.53M
Interest Expense % of Total Revenue77.17%0.00%0.00%150.00%1373.33%921.28%13767.44%1499.83%1589.83%19643.75%13941.64%892.90%99.33%

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.10M60.83M366.85M317.50M250.44M181.95M143.12M221.38M468.91M362.36M504.45M382.93M501.90M
Total Liabilities5.00M2.40M10.85M24.08M31.60M35.94M22.44M339.87M712.82M812.18M1.09B871.06M1.00B
Total Equity-2.90M58.42M356.00M293.42M218.84M146.01M120.68M-119.81M-242.17M-447.33M-586.99M-489.10M-499.57M
Cash350.00K59.10M175.91M8.08M23.87M16.82M15.51M34.91M181.10M104.64M265.45M143.43M88.33M
Total Debt1.76M265.00K2.47M8.21M7.27M6.91M14.85M275.55M645.66M723.77M726.72M504.17M878.12M
Net Debt1.41M-58.84M-173.44M127.00K-16.60M-9.91M-660.00K240.63M464.56M619.13M461.27M360.74M789.78M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-668.00K-5.35M-25.30M-38.59M-48.78M-63.38M-152.11M-171.72M-274.42M-337.51M-366.76M-391.24M-304.94M
Investing Cash Flow-3.00K-299.00K-175.22M-113.67M99.55M57.10M18.55M-19.81M-84.89M27.30M-30.47M-12.25M-149.80M
Financing Cash Flow905.00K64.41M317.33M-15.56M-34.98M-771.00K114.28M150.68M505.44M233.61M558.34M281.63M400.24M
Capital Expenditure3.00K299.00K2.24M6.56M34.81M13.10M4.29M1.67M33.56M78.16M30.58M6.89M3.85M
Free Cash Flow-671.00K-5.65M-27.55M-45.15M-83.59M-76.48M-156.40M-173.39M-307.98M-415.67M-397.34M-398.12M-308.78M
Dividends Paid------2.28M4.44M334.44M616.00K---
FCF to OCF100.45%105.58%108.86%117.00%171.37%120.67%102.82%100.97%112.23%123.16%108.34%101.76%101.26%
Dividend Paid to FCF-------1.46%-2.56%-108.59%-0.15%---

Earnings

Report DateSep 10, 2015Nov 12, 2015Mar 30, 2016May 16, 2016Aug 15, 2016Nov 10, 2016Mar 15, 2017May 8, 2017Aug 7, 2017Nov 7, 2017Mar 12, 2018May 7, 2018Aug 6, 2018Nov 7, 2018Mar 13, 2019May 8, 2019Aug 6, 2019Nov 5, 2019Mar 25, 2020May 11, 2020Aug 7, 2020Nov 9, 2020Mar 4, 2021May 14, 2021Aug 12, 2021Nov 12, 2021Mar 1, 2022May 10, 2022Aug 8, 2022Nov 9, 2022Mar 1, 2023May 11, 2023Aug 8, 2023Nov 9, 2023Mar 19, 2024May 9, 2024Aug 12, 2024Nov 12, 2024Mar 3, 2025May 7, 2025Aug 5, 2025Nov 4, 2025Mar 3, 2026May 7, 2026Aug 4, 2026Nov 3, 2026
EPS Estimate-0.13-0.10-0.23-0.37-0.58-0.45-0.43-0.36-0.31-0.32-0.33-0.34-0.38-0.37-0.31-0.23-0.24-0.18-0.20-0.17-0.19-0.18-0.18-0.41-0.12-0.20-0.21-0.22-0.24-0.21-0.22-0.27-0.23-0.18-0.18-0.16-0.15-0.18-0.13-0.16-0.10-0.10-0.11-0.07-0.09-0.08
EPS Actual-1.29-0.55-0.97-0.38-0.41-0.39-0.29-0.30-0.29-0.30-0.31-0.35-0.35-0.30-0.22-0.22-0.17-0.16-0.16-0.19-0.20-0.20-0.30-0.21-0.23-0.22-0.23-0.26-0.24-0.28-0.27-0.27-0.32-0.19-0.38-0.20-0.20-0.12-0.08-0.15-0.10-0.07-0.06-0.08-0.08-
Surprise-892.31%-450.00%-321.74%-2.70%29.31%13.33%32.56%16.67%6.45%6.25%6.06%-2.94%7.89%18.92%29.03%4.35%29.17%11.11%20.00%-11.76%-5.26%-11.11%-66.67%48.78%-91.67%-10.00%-9.52%-18.18%0.00%-33.33%-22.73%0.00%-39.13%-5.56%-111.11%-25.00%-33.33%33.33%38.46%6.25%0.00%30.00%45.75%-14.29%11.11%-
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hours-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap9.46B
Enterprise Value9.26B
Trailing P/E0.00
Forward P/E83.33
Price / Sales57.09
Price / Book0.00
EPS-0.96
Book Value-0.994
Revenue (TTM)165.79M
Gross Profit (TTM)164.70M
EBITDA-235.30M
Profit Margin0.00%
Operating Margin-120.41%
Return on Equity0.00%
Return on Assets-30.54%
Shares Outstanding1.06B
Shares Float406.69M
Beta0.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 14.25
  • Strong Buy
    3
  • Buy
    1

Ownership Breakdown

Institutions
19.94%
Insiders
62.16%
Retail / Other
17.90%

Top Institutional Holders

  • BlackRock Inc
    34.08M3.22%
  • State Street Corp
    21.40M2.02%
  • Vanguard Portfolio Management, LLC
    17.86M1.69%
  • Vanguard Capital Management, LLC
    15.69M1.48%
  • D. E. Shaw & Co LP
    11.55M1.09%
  • Two Sigma Investments LLC
    11.10M1.05%
  • Geode Capital Management, LLC
    9.85M0.93%
  • Millennium Management LLC
    5.58M0.53%
  • Northern Trust Corp
    3.57M0.34%
  • Morgan Stanley - Brokerage Accounts
    3.43M0.32%
  • The Goldman Sachs Group Inc
    3.23M0.31%
  • UBS Group AG
    3.20M0.30%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    13.52M1.28%
  • State Street® SPDR® S&P® Biotech ETF
    12.23M1.15%
  • iShares Russell 2000 ETF
    9.80M0.92%
  • Vanguard Small Cap Index
    9.55M0.90%
  • Vanguard MStar Small Cap Growth Indx Inv
    5.24M0.49%
  • Fidelity Small Cap Index
    4.22M0.40%
  • iShares Russell 2000 Growth ETF
    3.64M0.34%
  • iShares Biotechnology ETF
    3.07M0.29%